Seres Therapeutics (MCRB) Posts Q2 Loss of $1.45/Share

Seres Therapeutics (NASDAQ: MCRB) reported Q2 EPS of ($1.45), $1.15 worse than the analyst estimate of ($0.30).

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Nike names former Pfizer CFO David Denton as new finance chief